Grape King Bio (TPE:1707) Cyclically Adjusted Revenue per Share: NT$81.52 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1707 Grape King Bio Ltd TPE:1707
79 GF Score
Price NT$91.50
GF Value NT$144.15
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Grape King Bio Cyclically Adjusted Revenue per Share?

Grape King Bio TPE:1707 +0.77% 79 Cyclically Adjusted Revenue per Share is NT$81.52 as of Dec. 2025. GuruFocus rates TPE:1707 with a GF Score™ of 79/100 and a GF Value™ of NT$144.15 (Possible Value Trap). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Grape King Bio's adjusted revenue per share for the three months ended in Dec. 2025 was NT$20.013. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$81.52 for the trailing ten years ended in Dec. 2025.

During the past 12 months, Grape King Bio's average Cyclically Adjusted Revenue Growth Rate was 2.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 3.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 6.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Grape King Bio was 10.30% per year. The lowest was 3.90% per year. And the median was 8.60% per year.

As of today (2026-07-24), Grape King Bio's current stock price is NT$91.50. Grape King Bio's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2025 was NT$81.52. Grape King Bio's Cyclically Adjusted PS Ratio of today is 1.12.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Grape King Bio was 4.21. The lowest was 1.12. And the median was 2.23.


Grape King Bio  (TPE:1707) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Grape King Bio's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=91.50/81.52
=1.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Grape King Bio was 4.21. The lowest was 1.12. And the median was 2.23.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Grape King Bio Cyclically Adjusted Revenue per Share Related Terms


Grape King Bio Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Grape King Bio's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grape King Bio Cyclically Adjusted Revenue per Share Chart

Grape King Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 65.98 72.68 76.61 79.93 81.52

Grape King Bio Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 79.93 80.80 81.31 81.72 81.52

TPE:1707 vs ZTS, UTHR: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Grape King Bio's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grape King Bio Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grape King Bio's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Grape King Bio's Cyclically Adjusted PS Ratio falls into.


TPE:1707
79GF Score
Grape King Bio Ltd TPE:1707
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Grape King Bio Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Grape King Bio's adjusted Revenue per Share data for the three months ended in Dec. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=20.013/324.0540*324.0540
=20.013

Current CPI (Dec. 2025) = 324.0540.

Grape King Bio Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201603 14.700 238.132 20.004
201606 17.425 241.018 23.428
201609 16.986 241.428 22.799
201612 18.358 241.432 24.640
201703 14.671 243.801 19.500
201706 17.373 244.955 22.983
201709 16.544 246.819 21.721
201712 20.371 246.524 26.778
201803 14.183 249.554 18.417
201806 17.384 251.989 22.356
201809 16.331 252.439 20.964
201812 19.445 251.233 25.081
201903 14.777 254.202 18.838
201906 17.649 256.143 22.328
201909 15.490 256.759 19.550
201912 19.774 256.974 24.936
202003 14.716 258.115 18.475
202006 16.498 257.797 20.738
202009 15.853 260.280 19.737
202012 19.941 260.474 24.808
202103 13.481 264.877 16.493
202106 16.906 271.696 20.164
202109 16.155 274.310 19.085
202112 19.500 278.802 22.665
202203 13.799 287.504 15.553
202206 18.315 296.311 20.030
202209 16.733 296.808 18.269
202212 20.921 296.797 22.842
202303 14.924 301.836 16.023
202306 17.981 305.109 19.097
202309 17.179 307.789 18.087
202312 21.359 306.746 22.564
202403 15.772 312.332 16.364
202406 18.598 314.175 19.183
202409 19.519 315.301 20.061
202412 21.066 315.605 21.630
202503 15.133 319.799 15.334
202506 17.334 322.561 17.414
202509 16.317 324.800 16.280
202512 20.013 324.054 20.013

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of NT$81.52 mean?
Grape King Bio (TPE:1707) has a Cyclically Adjusted Revenue per Share of NT$81.52 as of Dec. 2025. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Grape King Bio and its competitors.
Is Grape King Bio's Cyclically Adjusted Revenue per Share too high?
Grape King Bio's current Cyclically Adjusted Revenue per Share is NT$81.52. Overall, Grape King Bio has a GF Score™ of 79/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Grape King Bio's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Grape King Bio's Cyclically Adjusted Revenue per Share of NT$81.52 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Grape King Bio and its competitors. Grape King Bio's current Cyclically Adjusted Revenue per Share is NT$81.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grape King Bio stock overvalued right now?
Based on GuruFocus' analysis, Grape King Bio (TPE:1707) is currently considered Possible Value Trap. The stock's GF Value™ is NT$144.15, compared to a current price of NT$91.50 — trading 36.5% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is NT$81.52. Grape King Bio's overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Grape King Bio (TPE:1707), the current Cyclically Adjusted Revenue per Share is NT$81.52 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Grape King Bio (TPE:1707) Overvalued in 2026?

Based on GuruFocus' analysis, Grape King Bio stock appears to be undervalued. The current stock price of NT$91.50 is trading 36.5% below its estimated GF Value™ of NT$144.15. GuruFocus considers Grape King Bio to be Possible Value Trap.

Key valuation signals for TPE:1707:

  • Cyclically Adjusted Revenue per Share: NT$81.52
  • GF Value™: NT$144.15 vs. price of NT$91.50 (36.5% below fair value)
  • GF Score™: 79/100 with 5 warning signs

No single metric tells the full story. See the TPE:1707 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Grape King Bio Business Description

Address Jinling Road, No. 402, Section 2, Pingzhen District, Pingzhen District, Taoyuan, TWN, 324
Grape King Bio Ltd is a specialty and generic drug manufacturing company engaged in producing and selling pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food. The company has three segments: MLM (Multi-Level Marketing), which is a direct seller of Pro-partner Inc, including the company's development and manufacturing products for Pro-partner Inc, the Distributors segment includes the company's self-owned brand products, and ODM/OEM (Original Design Manufacturer/Original Equipment Manufacturer) includes ODM/OEM in Taiwan and Shanghai. The group operates in three principal geographical areas - Taiwan, China, and Others, and it derives a majority of its revenue from Taiwan.
79GF Score

Get the complete analysis for TPE:1707

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$91.50
Price
NT$144.15
GF Value